Effect of sequential Minnesota-antilymphocyte globulin and cyclosporine therapy in primary cadaveric renal transplant recipients with delayed graft function.
Venkat
K K
KK
Division of Nephrology, Henry Ford Hospital, Detroit, Michigan 48202.
Kupin
W
W
Oh
H K
HK
D000961:Antilymphocyte Serum / Q000008:administration & dosage* / Q000627:therapeutic use; D002102:Cadaver; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007668:Kidney / Q000502:physiology; D016030:Kidney Transplantation; D007684:Kidney Tubules / Q000187:drug effects / Q000473:pathology; D009336:Necrosis; D011379:Prognosis
D000961:Antilymphocyte Serum; D003524:Cyclosporins